10813nam 2200541 450 991083104850332120240105184057.03-527-83049-93-527-83047-2(CKB)28285519600041(MiAaPQ)EBC30752950(Au-PeEL)EBL30752950(EXLCZ)992828551960004120231007d2024 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierOpen Access Databases and Datasets for Drug Discovery /edited by Antoine Daina, Michael Przewosny, and Vincent ZoeteFirst edition.Weinheim, Germany :Wiley-VCH,[2024]©20241 online resource (348 pages)Methods and Principles in Medicinal Chemistry Series9783527348398 Includes bibliographical references and index.Cover -- Title Page -- Copyright -- Contents -- Series Editors Preface -- Raimund Mannhold - A Personal Obituary from the Series Editors -- A Personal Foreword -- Chapter 1 Open Access Databases and Datasets for Computer‐Aided Drug Design. A Short List Used in the Molecular Modelling Group of the SIB -- References -- Part I Small Molecules -- Chapter 2 PubChem: A Large‐Scale Public Chemical Database for Drug Discovery -- 2.1 Introduction -- 2.2 Data Content and Organization -- 2.3 Tools and Services -- 2.3.1 PubChem Search -- 2.3.2 Summary Pages -- 2.3.3 Literature Knowledge Panel -- 2.3.4 2D and 3D Neighbors -- 2.3.5 Classification Browser -- 2.3.6 Identifier Exchange Service -- 2.3.7 Programmatic Access -- 2.3.8 PubChem FTP Site and PubChemRDF -- 2.4 Drug‐ and Lead‐Likeness of PubChem Compounds -- 2.5 Bioactivity Data in PubChem -- 2.6 Comparison with Other Databases -- 2.7 Use of PubChem Data for Drug Discovery -- 2.8 Summary -- Acknowledgments -- References -- Chapter 3 DrugBank Online: A How‐to Guide -- 3.1 Introduction -- 3.2 DrugBank -- 3.2.1 Overview of DrugBank -- 3.2.2 DrugBank Datasets -- 3.2.2.1 Drug Cards: An Overview and Navigation Guide -- 3.2.2.2 Identification -- 3.2.2.3 Pharmacology -- 3.2.2.4 Categories -- 3.2.2.5 Properties -- 3.2.2.6 Targets, Enzymes, Carriers, and Transporters -- 3.2.2.7 References -- 3.3 Protocols -- 3.3.1 General Workflows -- 3.3.1.1 Using DrugBank Online's Search Functionality -- 3.3.1.2 Using DrugBank Online's Advanced Search Functionality -- 3.3.1.3 Browsing Drugs Using DrugBank Online's Drug Categories -- 3.3.2 Identifying Chemicals and Relevant Sequences -- 3.3.2.1 Searching Using Chemical Structure Search -- 3.3.2.2 Using Sequence Search to Find Similar Targets -- 3.3.3 Extracting DrugBank Datasets for ML -- 3.4 Research Using DrugBank -- 3.5 Discussion and Conclusions -- References.Chapter 4 Bioisosteric Replacement for Drug Discovery Supported by the SwissBioisostere Database -- 4.1 Introduction -- 4.1.1 Concept of Isosterism and Bioisosterism -- 4.1.2 Classical vs. Non‐classical Bioisostere and Further Molecular Replacements -- 4.1.3 Bioisosteric Replacement in Drug Discovery -- 4.2 Construction and Dissemination of SwissBioisostere -- 4.2.1 Intention and Requirements -- 4.2.2 Bioactivity Data -- 4.2.3 Nonsupervised Matched Molecular Pair Analysis -- 4.2.4 Database -- 4.2.5 Web Interface -- 4.3 Content of SwissBioisostere -- 4.3.1 Global Content -- 4.3.2 Biological and Chemical Contexts -- 4.3.3 Fragment Shape Diversity -- 4.4 Usage of SwissBioisostere -- 4.4.1 Website Usage -- 4.4.2 Most Frequent Requests -- 4.4.3 Examples Related to Drug Discovery -- 4.4.3.1 Use Cases -- 4.4.3.2 Replacing Unwanted Chemical Groups -- 4.4.3.3 Optimization of Passive Absorption and Blood-Brain Barrier Diffusion -- 4.4.3.4 Reduction of Flexibility -- 4.4.3.5 Reduction of Aromaticity/Escape from Flatland -- 4.5 Conclusive Remarks -- Acknowledgment -- References -- Part II Macromolecular Targets and Diseases -- Chapter 5 The Protein Data Bank (PDB) and Macromolecular Structure Data Supporting Computer‐Aided Drug Design -- 5.1 Introduction -- 5.2 Small Molecule Data in Protein Data Bank (PDB) Entries -- 5.2.1 What Data are in the PDB Archive? -- 5.2.2 Definition of Small Molecules in OneDep -- 5.3 Small Molecule Dictionaries -- 5.3.1 wwPDB Chemical Component Dictionary (CCD) -- 5.3.2 The Peptide Reference Dictionary -- 5.4 Additional Ligand Annotations in the PDB Archive -- 5.4.1 Linkage Information -- 5.4.2 Carbohydrates -- 5.5 Validation of Ligands in the Worldwide Protein Data Bank (wwPDB) -- 5.5.1 Various Criteria and Software Used for Validating Ligand in Validation Reports -- 5.5.2 Identification of Ligand of Interest (LOI).5.5.3 Geometric and Conformational Validation -- 5.5.4 Ligand Fit to Experimental Electron Density Validation -- 5.5.5 Accessing wwPDB Validation Reports from PDBe Entry Pages -- 5.5.6 Other Planned Improvements to Enhance Ligand Validation -- 5.6 PDBe Tools for Ligand Analysis -- 5.6.1 Ligand Interactions -- 5.6.1.1 Classifying Ligand Interactions -- 5.6.1.2 Data Availability -- 5.6.2 Ligand Environment Component -- 5.6.3 Chemistry Process and FTP -- 5.6.4 PDBeChem Pages -- 5.7 Ligand‐Related Annotations in the PDBe‐KB -- 5.7.1 Introduction to PDBe‐KB -- 5.7.2 Data Access Mechanisms for Ligand‐Related Annotations -- 5.7.3 Ligand‐Related Annotations on the Aggregated Views of Proteins -- 5.8 Case Study: Using PDB Data to Support Drug Discovery -- 5.9 Conclusions and Outlook -- 5.9.1 Upcoming Features and Improvements -- References -- Chapter 6 The SWISS‐MODEL Repository of 3D Protein Structures and Models -- 6.1 Introduction -- 6.2 SMR Database Content and Model Providers -- 6.2.1 PDB -- 6.2.2 SWISS‐MODEL -- 6.2.3 AlphaFold Database -- 6.2.4 ModelArchive -- 6.3 Protein Feature Annotation and Cross‐References to Computational Resources -- 6.3.1 Structural Features, Ligands, and Oligomers -- 6.3.2 SWISS‐MODEL associated tools -- 6.3.3 Web and API Access -- 6.4 Quality Estimates and Benchmarking -- 6.5 Binding Site Conformational States -- 6.6 SMR and Computer‐Aided Structure‐based Drug Design -- 6.7 Conclusion and Outlook -- References -- Chapter 7 PDB‐REDO in Computational‐Aided Drug Design (CADD) -- 7.1 History and Concepts -- 7.1.1 X‐ray Structure Models -- 7.1.2 PDB‐REDO Development -- 7.1.2.1 First Uniformity -- 7.1.2.2 Automatic Rebuilding of Protein Backbone and Side Chains -- 7.1.2.3 Automated Model Completion Approaches -- 7.1.2.4 Systematic Integration of Structural Knowledge -- 7.1.2.5 Overview of PDB‐REDO Pipeline.7.2 Structure Improvements by PDB‐REDO -- 7.2.1 Parametrization and Rebuilding Effects on Small Molecule Ligands -- 7.2.1.1 Re‐refinement Improves Ligand Conformation -- 7.2.1.2 Side Chain Rebuilding Improves Ligand Binding Sites -- 7.2.1.3 Histidine Flip and Improved Ligand Parameterization -- 7.2.2 Building of Protein Loops and Ligands into Protein Structure Models -- 7.2.2.1 Loop Building Completes a Binding Site Region -- 7.2.2.2 Loop Building Results in Improved Binding Sites -- 7.2.2.3 Building new Compounds into Density -- 7.2.3 Nucleic Acid Improvements by PDB‐REDO -- 7.2.4 Glycoprotein Structure Model Rebuilding -- 7.2.5 Metal Binding Sites -- 7.2.6 Limitations of the PDB‐REDO Databank -- 7.3 Access the PDB‐REDO Databank and Metadata -- 7.3.1 Downloading and Inspecting Individual PDB‐REDO Entries -- 7.3.2 Data Available in PDB‐REDO Entries -- 7.3.3 Usage of the Uniform and FAIR Validation Data -- 7.3.4 Creating Datasets from the PDB‐REDO Databank -- 7.3.5 Submitting Structure Models to the PDB‐REDO Pipeline -- 7.4 Conclusions -- Acknowledgments and Funding -- References -- Chapter 8 Pharos and TCRD: Informatics Tools for Illuminating Dark Targets -- 8.1 Introduction -- 8.2 Methods -- 8.2.1 Data Organization -- 8.2.1.1 Target Alignment -- 8.2.1.2 Disease Alignment -- 8.2.1.3 Ligand Alignment -- 8.2.1.4 Data and UI Updates -- 8.2.2 Programmatic Access and Data Download -- 8.2.3 UI Organization -- 8.2.3.1 List Pages -- 8.2.3.2 Details Pages -- 8.2.3.3 Search -- 8.2.3.4 Tutorials -- 8.2.4 Analysis Methods Within Pharos -- 8.2.4.1 Searching for Ligands -- 8.2.4.2 Finding Targets by Amino Acid Sequence -- 8.2.4.3 Finding Targets with Similar Annotations -- 8.2.4.4 Finding Targets with Predicted Activity -- 8.2.4.5 Enrichment Scores for Filter Values -- 8.3 Use Cases -- 8.3.1 Hypothesizing the Role of a Dark Target -- 8.3.1.1 Primary Documentation.8.3.1.2 List Analysis -- 8.3.1.3 Downloading Data -- 8.3.1.4 Variations on this Use Case -- 8.3.2 Characterizing a Novel Chemical Compound -- 8.3.2.1 Finding Predicted Targets -- 8.3.2.2 Analyzing Similar Ligands -- 8.3.2.3 Ligand Details Pages -- 8.3.2.4 Variations on this Use Case -- 8.3.3 Investigating Diseases -- 8.4 Discussion -- Funding -- References -- Part III Users' Points of View -- Chapter 9 Mining for Bioactive Molecules in Open Databases -- 9.1 Introduction -- 9.2 Main Tools for Virtual Screening -- 9.2.1 ADMET and PAINS Filtering -- 9.2.2 Protein-Ligand Docking -- 9.2.3 Pharmacophore Search -- 9.2.4 Shape/Electrostatic Similarity -- 9.2.5 Protein‐Structure Databases -- 9.2.6 The Protein Data Bank -- 9.2.7 The PDB‐REDO Databank -- 9.2.8 The SWISS‐MODEL Repository -- 9.2.9 The AlphaFold Protein Structure Database -- 9.3 Validating Binding Site and Ligand Coordinates in Three‐Dimensional Protein Complexes -- 9.4 Databases for Searching New Drugs -- 9.4.1 COCONUT -- 9.4.2 GDBs -- 9.4.3 ZINC20 -- 9.5 Databases of Bioactive Molecules -- 9.5.1 The BindingDB Database -- 9.5.2 PubChem -- 9.5.3 ChEMBL -- 9.6 Databases of Inactive/Decoy Molecules -- 9.6.1 Collecting Experimentally Inactive Compounds from PubChem -- 9.6.2 Collecting Presumed Inactive Compounds from Decoy Databases -- 9.6.3 Building Custom‐Based Decoy Sets -- 9.7 Main Metrics for Evaluating the Success of a Virtual Screening -- 9.8 Concluding Remarks -- References -- Chapter 10 Open Access Databases - An Industrial View -- 10.1 Academic vs. Industrial Research -- 10.2 Scaffold‐Hopping -- 10.3 Virtual‐Screening -- References -- Index -- EULA.Methods and principles in medicinal chemistry.DrugsDesignData processingDrug developmentData processingDrugsDesignData processing.Drug developmentData processing.615.19Daina AntoinePrzewosny MichaelZoete VincentMiAaPQMiAaPQMiAaPQBOOK9910831048503321Open Access Databases and Datasets for Drug Discovery4121656UNINA02153nam0 22004091i 450 UON0052782520250402122356.10978-90-04-53966-2v. 1978-90-04-72273-6v. 220250311d2024 |0itac50 baengNL|||| |||||ˆA ‰Companion to Nō and Kyōgen Theatreedited by Yamanaka Reiko, Monica Bethe, Eike Grossmann, Tom Hare, Diego Pellecchia, and Michael WatsonLeidenBostonBrill20242 v. (xxxiii, xxxiii, 1079 p.ill.)25 cm001UON002736412001 Handbook of Oriental Studies. 5Japan19 (1-2)Teatro giapponeseTeatro KyōgenUONC008210FITeatro giapponeseTeatro KyōgenStoriaUONC104622FITeatro giapponeseTeatro NōUONC001163FITeatro giapponeseTeatro NōStoriaUONC104621FIGIA IX HGIAPPONE - ARTI - MUSICA, TEATRO, CINEMA, DANZAABetheMonicaUONV297090GroßmannEikeUONV297091HareThomas BlenmanUONV032779PellecchiaDiegoUONV297092WatsonMichaelUONV003266Yamanaka ReikoUONV297089BrillUONV245886650ITSOL20250411RICAUON00527825SIBA - SISTEMA BIBLIOTECARIO DI ATENEOSI GIA IX H 275 (1) SI 52509 7 275 (1) SIBA - SISTEMA BIBLIOTECARIO DI ATENEOSI GIA IX H 275 (2) SI 52514 7 275 (2) SIBA - SISTEMA BIBLIOTECARIO DI ATENEOSI202533 1J 20250311Bolla n. 6 del 26.3.2025. SIBA - SISTEMA BIBLIOTECARIO DI ATENEOSI202534 1J 20250311Bolla n. 6 del 26.3.2025. Companion to Nō and Kyōgen Theatre4343139UNIOR